"Leading health experts [1] today urge the deployment of alternative trial designs to fast-track the evaluation of new Ebola treatments. In a letter to The Lancet, 17 senior health professionals and medical ethicists, from Africa, Europe, and USA, argue that although randomised controlled trials (RCTs) provide robust evidence in most circumstances, the lack of effective treatment options for Ebola, high mortality with the current standard of care, and the paucity of effective health care systems in the affected regions means that alternative trial designs need to be considered."

New financial disclosure documents released this month by the National Security Agency (NSA) show that Keith Alexander, who served as its director from August 2005 until March 2014, had thousands of dollars of investments during his tenure in a handful of technology firms.